Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

Giampaolo Merlini; Shayna Sarosiek; Giulia Benevolo; Xinxin Cao; Meletios Dimopoulos; Ramon Garcia-Sanz; Moshe E Gatt; Carlos Fernandez de Larrea; Jesus San-Miguel; Steven P Treon; Monique C Minnema

doi:10.1053/j.seminhematol.2023.03.002

Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

Giampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, Xinxin Cao, Meletios Dimopoulos, Ramon Garcia-Sanz, Moshe E Gatt, Carlos Fernandez de Larrea, Jesus San-Miguel, Steven P Treon, Monique C Minnema

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM.

Original language	English
Pages (from-to)	113-117
Number of pages	5
Journal	Seminars in Hematology
Volume	60
Issue number	2
Early online date	29 Mar 2023
DOIs	https://doi.org/10.1053/j.seminhematol.2023.03.002
Publication status	Published - Mar 2023

Keywords

AL amyloidosis
Diagnostic criteria
Response assessment
Therapy
Waldenström macroglobulinemia

Access to Document

10.1053/j.seminhematol.2023.03.002

Cite this

Merlini, G., Sarosiek, S., Benevolo, G., Cao, X., Dimopoulos, M., Garcia-Sanz, R., Gatt, M. E., Fernandez de Larrea, C., San-Miguel, J., Treon, S. P., & Minnema, M. C. (2023). Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis. Seminars in Hematology, 60(2), 113-117. https://doi.org/10.1053/j.seminhematol.2023.03.002

@article{9d1326d0521d4230adbdb1f1ccd8b229,

title = "Report of Consensus Panel 6 from the 11 th International Workshop on Waldenstr{\"o}m's Macroglobulinemia on Management of Waldenstr{\"o}m's Macroglobulinemia Related Amyloidosis",

abstract = "Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenstr{\"o}m's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenstr{\"o}m macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM.",

keywords = "AL amyloidosis, Diagnostic criteria, Response assessment, Therapy, Waldenstr{\"o}m macroglobulinemia",

author = "Giampaolo Merlini and Shayna Sarosiek and Giulia Benevolo and Xinxin Cao and Meletios Dimopoulos and Ramon Garcia-Sanz and Gatt, {Moshe E} and {Fernandez de Larrea}, Carlos and Jesus San-Miguel and Treon, {Steven P} and Minnema, {Monique C}",

note = "Funding Information: The authors gratefully acknowledge Beigene Pharmaceuticals, Abbvie/Pharmacyclics, Janssen Pharmaceuticals, the International Waldenstr{\"o}m's Macroglobulinemia Foundation, and Cellectar Biosciences, Inc. for their support of the 11th International Workshop on Waldenstr{\"o}m's Macroglobulinemia. Consensus panel reports of IWWM-11 are for educational purposes and should not be construed as offering specific medical advice for patients. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = mar,

doi = "10.1053/j.seminhematol.2023.03.002",

language = "English",

volume = "60",

pages = "113--117",

journal = "Seminars in Hematology",

issn = "0037-1963",

publisher = "W.B. Saunders Ltd",

number = "2",

}

Merlini, G, Sarosiek, S, Benevolo, G, Cao, X, Dimopoulos, M, Garcia-Sanz, R, Gatt, ME, Fernandez de Larrea, C, San-Miguel, J, Treon, SP & Minnema, MC 2023, 'Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis', Seminars in Hematology, vol. 60, no. 2, pp. 113-117. https://doi.org/10.1053/j.seminhematol.2023.03.002

Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis. / Merlini, Giampaolo; Sarosiek, Shayna; Benevolo, Giulia et al.
In: Seminars in Hematology, Vol. 60, No. 2, 03.2023, p. 113-117.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

AU - Merlini, Giampaolo

AU - Sarosiek, Shayna

AU - Benevolo, Giulia

AU - Cao, Xinxin

AU - Dimopoulos, Meletios

AU - Garcia-Sanz, Ramon

AU - Gatt, Moshe E

AU - Fernandez de Larrea, Carlos

AU - San-Miguel, Jesus

AU - Treon, Steven P

AU - Minnema, Monique C

N1 - Funding Information: The authors gratefully acknowledge Beigene Pharmaceuticals, Abbvie/Pharmacyclics, Janssen Pharmaceuticals, the International Waldenström's Macroglobulinemia Foundation, and Cellectar Biosciences, Inc. for their support of the 11th International Workshop on Waldenström's Macroglobulinemia. Consensus panel reports of IWWM-11 are for educational purposes and should not be construed as offering specific medical advice for patients. Publisher Copyright: © 2023 Elsevier Inc.

PY - 2023/3

Y1 - 2023/3

N2 - Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM.

AB - Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM.

KW - AL amyloidosis

KW - Diagnostic criteria

KW - Response assessment

KW - Therapy

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=85152564850&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2023.03.002

DO - 10.1053/j.seminhematol.2023.03.002

M3 - Article

C2 - 37099030

SN - 0037-1963

VL - 60

SP - 113

EP - 117

JO - Seminars in Hematology

JF - Seminars in Hematology

IS - 2

ER -

Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this